https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

Rate of Bone Loss on ART Slows After the First Year Img

Rate of Bone Loss on ART Slows After the First Year

Reassuring data that the initial loss in bone mineral density during the first year of antiretroviral therapy slowed during subsequent years.

Statin Use Might Reduce Risk of Cancer in HIV-Positive People Img

Statin Use Might Reduce Risk of Cancer in HIV-Positive People

A large case-control analysis reported an overall association between statin use and a reduced risk of virus-mediated cancers in HIV-positive people.

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment Img

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment

New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin Img

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Low Dietary Calcium Tied to Low BMD With HCV but Not HIV Img

Low Dietary Calcium Tied to Low BMD With HCV but Not HIV

Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.

In a Large HIV Group, Only 36% of Those Needing Statins Received Statins Img

In a Large HIV Group, Only 36% of Those Needing Statins Received Statins

The majority of HIV-positive people with a statin indication by current guidelines are not receiving a statin, according to an analysis at a St. Louis HIV clinic.

Conversations on HIV-Related Stigma and Curing HCV Coinfection Img

Conversations on HIV-Related Stigma and Curing HCV Coinfection

HIV.gov shares their conversations with several presenters and participants at USCA 2017 about HIV-related stigma and curing hepatitis C coinfection among people living with HIV.

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study Img

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).